pegasu earn wing reiter op pt
reiter outperform rate increas pt
follow posit phase pegasu data pnh slide top-lin improv
adjust mean hemoglobin addit correspond
secondari result pegasu favor outstrip bullish scenario
analysi written previous number clinic question
resoundingli address expect road commerci pegcetacoplan
domin pre-commerci regulatori activ anticip
addit data june eha follow regulatori updat middl
potenti nda file estim end given
impress clinic result pegasu readout stay bullish
impress top-lin chang hb result join strike
pegcetacoplan-tr patient transfusion-fre compar
eculizumab-tr patient despit attent hemolysis-associ
dropout note conserv estim hb would maintain
top-lin result also note superiority-focus studi includ
patient treat meaning higher dose eculizumab label
safeti came line expect compar rate sever advers
event toler profil expect sc infus higher rate isr
eculizumab fatigu rate pegcetacoplan arm versu eculizumab
arm notabl observ underscor facit fatigu score improv
delta point week mmrm observ respect
commerci like plan meet agenc
anticip file estim account inclus
pegcetacoplan safeti exposur potenti one two-year
gap expand pnh label front on-going monotherapi princ
studi pegasu provid posit readthrough could support expans
debat clinic benefit patient less sever anemia could
persist highlight rather unnot poster last month
note complement blockad sever pnh popul
perceiv surviv benefit compar milder untreat pnh popul despit
similarli correspond biomark could suggest real import
address subclin diseas
increas pt updat estim base
strong clinic result believ support strong adopt pegcetacoplan
pnh base clinic profil pegcetacoplan estim peak market
penetr rais po candid pnh
account primarili pt chang
year price histori
develop pegcetacoplan
current phase develop
pnh geograph atrophi ga
found apelli base
analyst certif import disclosur see disclosur
inhibit potenti address
two potenti blockbust indic signific unmet
need ga pnh believ potenti
address meaning proport pnh market
alreadi commerci develop alexion
therapeut soliri eculizumab ultomiri
ravulizumab ga howev treatment exist
sever late-stag diseas believ opportun set
eye could rival potenti exceed
regeneron flagship eylea aflibercept franchis
constrast also face brand ranibizumab/brolucizumab
demonstr hemoglobin improv least
improv secondari compar eculizumab phase
enrol phase derbi oak complet
complet enrol phase ga studi kol call note
phase derbi oak readout ga
demonstr hemoglobin improv improv
transfus independ compar eculizumab phase
enrol phase derbi oak complet end
demonstr clinic signific benefit ga pnh
cad
employ composit valuat methodolog biotechnolog compani util revenu multipl discount cash flow analysi
respect development-stag compani place greater weight revenu multipl compar dcf analysi due
latter sensit long-run assumpt price target blend revenu multipl calcul dcf
valuat
appli revenu multipl pnh multipl ga lie rang industri averag
probabl success drug approv pnh ga
appli discount rate line smid-cap biotech
clinic efficaci fail meet clinic efficaci endpoint program pnh ga cad
clinic safeti safeti signal emerg clinic studi
manufactur risk manufactur issu could hinder regulatori approv limit penetr commerci market
regulatori risk regul rais addit requir concern around develop delay prevent regulatori approv
commercial/competitive/reimburs risk competit pressur develop asset could lower market potenti
negoti payor could limit market opportun
financ apelli may requir addit fund conduct addit studi commerci
statement oper
thousand except per share
good sold
research develop
loss extinguish debt
loss remeasur develop deriv liabil
loss remeasur fair valu warrant deriv
comprehens loss net tax
net profit loss per common share basic dilut
weight average common share basic dilut
thousand
cash equival
refund research develop credit
properti equip net
liabil stockhold equiti
current portion long-term debt
current portion right use liabil
addit paid capit
accumul comprehens incom
total liabil stockhold equiti
statement cashflow
thousand
loss earli extinguish debt
loss remeasur fair valu warrant
amort right-of-us asset
accret discount
refund research develop credit
net cash use oper activ
purchas properti equip
net cash use invest activ
issuanc seri convert prefer stock net issuanc
repay promissori note
payment cap call transact associ cost
proce issuanc common stock net issuanc cost
proce develop deriv liabil
proce exercis stock option warrant
proce issuanc term loan net issuanc cost
proce issuanc promissori note payabl
affili stockhold
proce issuanc common stock warrant
repay term loan
net cash provid financ activ
effect exchang rate chang cash cash equival
net increas decreas cash equival
cash equival begin period
cash equival end period
million
patient pnh
pnh patient treat
patient pnh
pnh patient treat
million
patient ga
ga patient treat
adult year age
patient ga
ga patient treat
popul
/share total
million except per share
assumpt multipl tab
nwc revenu
npv
million except per share
